IN THE CLAIMS

Please cancel claims 1-59 and add new claims 60-97 as follows:

Claims 1-59 (Cancelled).

Claim 60 (New): A compound having a structural formula, including a salt thereof, a solvate thereof, or an N-oxide thereof, selected from the group consisting of:

































Claim 61 (New): A composition comprising at least one compound according to claim 60 and a pharmaceutically acceptable carrier.

Claim 62 (New): The composition according to claim 61, wherein said composition further comprises at least one pharmaceutically acceptable additive selected from the group consisting of fillers, extenders, binders, disintegrating agents, dissolution aids/accelerators, suspending agents, emulsifying agents, wetting agents, stabilizers, and preservatives.

Claim 63 (New): The composition according to claim 61, wherein said composition is in the form of a tablet, a granule, a capsule, a powder, a solution, a suspension, an emulsion, an oil, a syrup, an elixir, an ointment, a gel, a cream, a lotion, a spray, or a plaster.

Claim 64 (New): The composition according to claim 61, wherein said composition is suitable for oral, topical, or injection administration.

Claim 65 (New): A process for preparing a composition comprising combining at least one compound according to claim 60 with a pharmaceutically acceptable carrier.

Claim 66 (New): The process according to claim 65, wherein said process further comprises combining with said at least one compound and said pharmaceutically acceptable carrier, at least one pharmaceutically acceptable additive selected from the group consisting of fillers, extenders, binders, disintegrating agents, dissolution aids/accelerators, suspending agents, emulsifying agents, wetting agents, stabilizers, and preservatives.

Claim 67 (New): A method of inhibiting activated blood coagulation factor X comprising administering to a mammal in need thereof a therapeutically effective amount of the composition according to claim 61.

Claim 68 (New): The method according to claim 67, wherein said therapeutically effective amount ranges from 1 mg to 1000 mg per day of said at least one compound present within said composition.

Claim 69 (New): The method according to claim 67, wherein said therapeutically effective amount ranges from 0.1 mg to 200 mg per kg of body weight of said mammal per day of said at least one compound present within said composition.

Claim 70 (New): The method according to claim 67, wherein the administration of said composition ranges from one to four times per day.

Claim 71 (New): A method of treating and/or preventing thrombosis or embolism comprising administering to a mammal in need thereof a therapeutically effective amount of the composition according to claim 61.

Claim 72 (New): The method according to claim 71, wherein said therapeutically effective amount ranges from 1 mg to 1000 mg per day of said at least one compound present within said composition.

Claim 73 (New): The method according to claim 71, wherein said therapeutically effective amount ranges from 0.1 mg to 200 mg per kg of body weight of said mammal per day of said at least one compound present within said composition.

Claim 74 (New): The method according to claim 71, wherein the administration of said composition ranges from one to four times per day.

Claim 75 (New): A method of treating and/or preventing a condition comprising administering to a mammal in need thereof a therapeutically effective amount of the composition according to claim 61, wherein said condition is selected from the group consisting of cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombosis formation and reocclusion after angioplasty, systemic inflammatory

response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, and blood clotting upon blood drawing.

Claim 76 (New): The method according to claim 75, wherein said therapeutically effective amount ranges from 1 mg to 1000 mg per day of said at least one compound present within said composition.

Claim 77 (New): The method according to claim 75, wherein said therapeutically effective amount ranges from 0.1 mg to 200 mg per kg of body weight of said mammal per day of said at least one compound present within said composition.

Claim 78 (New): The method according to claim 75, wherein the administration of said composition ranges from one to four times per day.

Claim 79 (New): A compound having a stereochemical structural formula, including a salt thereof, a solvate thereof, or an N-oxide thereof, selected from the group consisting of:

































Claim 80 (New): A composition comprising at least one compound according to claim 79 and a pharmaceutically acceptable carrier.

Claim 81 (New): The composition according to claim 80, wherein said composition further comprises at least one pharmaceutically acceptable additive selected from the group consisting of fillers, extenders, binders, disintegrating agents, dissolution aids/accelerators, suspending agents, emulsifying agents, wetting agents, stabilizers, and preservatives.

Claim 82 (New): The composition according to claim 80, wherein said composition is in the form of a tablet, a granule, a capsule, a powder, a solution, a suspension, an emulsion, an oil, a syrup, an elixir, an ointment, a gel, a cream, a lotion, a spray, or a plaster.

Claim 83 (New): The composition according to claim 80, wherein said composition is suitable for oral, topical, or injection administration.

Claim 84 (New): A process for preparing a composition comprising combining at least one compound according to claim 79 with a pharmaceutically acceptable carrier.

Claim 85 (New): The process according to claim 84, wherein said process further comprises combining with said at least one compound and said pharmaceutically acceptable carrier, at least one pharmaceutically acceptable additive selected from the group consisting of fillers, extenders, binders, disintegrating agents, dissolution aids/accelerators, suspending agents, emulsifying agents, wetting agents, stabilizers, and preservatives.

Claim 86 (New): A method of inhibiting activated blood coagulation factor X comprising administering to a mammal in need thereof a therapeutically effective amount of the composition according to claim 80.

Claim 87 (New): The method according to claim 86, wherein said therapeutically effective amount ranges from 1 mg to 1000 mg per day of said at least one compound present within said composition.

Claim 88 (New): The method according to claim 86, wherein said therapeutically effective amount ranges from 0.1 mg to 200 mg per kg of body weight of said mammal per day of said at least one compound present within said composition.

Claim 89 (New): The method according to claim 86, wherein the administration of said composition ranges from one to four times per day.

Claim 90 (New): A method of treating and/or preventing thrombosis or embolism comprising administering to a mammal in need thereof a therapeutically effective amount of the composition according to claim 80.

Claim 91 (New): The method according to claim 90, wherein said therapeutically effective amount ranges from 1 mg to 1000 mg per day of said at least one compound present within said composition.

Claim 92 (New): The method according to claim 90, wherein said therapeutically effective amount ranges from 0.1 mg to 200 mg per kg of body weight of said mammal per day of said at least one compound present within said composition.

Claim 93 (New): The method according to claim 90, wherein the administration of said composition ranges from one to four times per day.

Claim 94 (New): A method of treating and/or preventing a condition comprising administering to a mammal in need thereof a therapeutically effective amount of the composition according to claim 80, wherein said condition is selected from the group consisting of cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombosis formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, and blood clotting upon blood drawing.

Claim 95 (New): The method according to claim 94, wherein said therapeutically effective amount ranges from 1 mg to 1000 mg per day of said at least one compound present within said composition.

Claim 96 (New): The method according to claim 94, wherein said therapeutically effective amount ranges from 0.1 mg to 200 mg per kg of body weight of said mammal per day of said at least one compound present within said composition.

Claim 97 (New): The method according to claim 94, wherein the administration of said composition ranges from one to four times per day.